All eyes are on Tesaro (NASDAQ:TSRO) cancer stock following the fade from March this year. Reports suggest that its ovarian cancer data from TOPACIO continues to look good and many firms have upgraded or continue to rate the stock with a PT near or exceeding $200. CS suggests a PT of $198, OPCO $199 and Citi says $216 to name a few. Note: This particular stock has been volatile and it looks attractive to take a position on the sharp fade relatively soon, possibly this week.
Also, the stock could be in play, but we will have to see it through despite the pipeline and good data. The stock is a darling with many biotech investors following quality stocks in this sector. Regardless, the lows--following a recent fade--appear to be setting in per the chart below. I do expect the stock to be higher over the next six months, then lets see how it looks compared to its peers.
Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in TSRO over the next 72 hours.